Abstract: Background: Accurate methods for blood glucose measurement are imperative to directing therapy in patients with dysglycemic conditions. AlphaTRAK® 2 (AT2) Blood Glucose Monitoring System is currently available for glucose measurement in dogs and cats. A newer generation device, AlphaTrak 3 (AT3), has been developed to continue to provide accurate blood glucose monitoring.
Objectives: Demonstrate clinical accuracy of AT3 in a clinical cohort of cats compared to a reference method.
Animals: 62 client-owned cats with normoglycemia and dysglycemia.
Methods: 3 mL blood was collected from each cat. Whole blood aliquots were immediately tested concurrently on three AT3 devices using three lots of test strips. Plasma glucose was also measured in triplicate by Beckman Coulter Chemistry Analyzer. Success was defined as 95% of measured values falling within the International Organization for Standardization (ISO) accuracy threshold and 99% of measurements falling within zones A and B of the Consensus Error Grid (CEG). A linear regression model was also used to demonstrate correlation.
Results: 179 of 186 glucose measurements (96.2%) fell within the ISO accuracy threshold. 100% of measurements fell within CEG zones A and B. The linear regression analysis correlation coefficient (R²) of 0.99 indicated good correlation across the full dynamic range of glucose concentrations (20 – 750 mg/dL).
Conclusions and Clinical Importance: The analytical performance of AlphaTrak 3 was comparable to the reference analyzer over a range of feline blood glucose measurements, confirming that AlphaTrak 3 met the ISO success criteria and can be utilized for clinical decision making in diabetic cats.
